Compare AGIO & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGIO | WD |
|---|---|---|
| Founded | 2007 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2013 | 2010 |
| Metric | AGIO | WD |
|---|---|---|
| Price | $27.25 | $51.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $38.88 | ★ $76.00 |
| AVG Volume (30 Days) | ★ 1.3M | 188.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.64 |
| Revenue | $43,011,000.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $76.75 | $20.60 |
| Revenue Next Year | $170.73 | $7.79 |
| P/E Ratio | ★ N/A | $31.15 |
| Revenue Growth | N/A | ★ 8.99 |
| 52 Week Low | $22.24 | $42.12 |
| 52 Week High | $46.00 | $90.00 |
| Indicator | AGIO | WD |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 59.59 |
| Support Level | $26.03 | $48.44 |
| Resistance Level | $29.69 | $52.44 |
| Average True Range (ATR) | 1.36 | 1.57 |
| MACD | -0.19 | 0.23 |
| Stochastic Oscillator | 25.72 | 70.50 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.